Recurrent gene fusions in prostate cancer
AssigneesThe Brigham and Women's Hospital, Inc., The Regents of the University of Michigan
InventorsScott Tomlins, Daniel Rhodes, Arul Chinnaiyan, Rohit Mehra, Mark A. Rubin, Xiao-Wei Sun, Sven Perner, Charles Lee, Francesca Demichelis
Life of this patent
Estimating the term…
Abstract
Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
Claims23
A composition comprising an oligonucleotide probe covalently labeled with a detectable label and comprising a sequence that hybridizes to a junction of a chimeric nucleic acid molecule in which a 5′ portion of the chimeric nucleic acid molecule is from a TMPRSS2 gene and a 3′ portion of the chimeric nucleic acid molecule is from an ETS family member gene, wherein the ETS family member gene is selected from the group consisting of ERG, ETV1 (ER81), FLI1, ETS1, ETS2, ELK1, ETV6 (TEL1), ETV7 (TEL2), GABPa, ELF1, ETV4 (E1AF;
- PEA3), ETV5 (ERM), ERF, PEA3/E1AF, PU.1, ESE1/ESX, SAP1 (ELK4), ETV3(METS), EWS/FLI1, ESE1, ESE2 (ELF5), ESE3, PDEF, NET (ELK3;
- SAP2), NERF (ELF2), and FEV.
A composition comprising an oligonucleotide probe covalently labeled with a detectable label and comprising a sequence that hybridizes to a junction of a chimeric nucleic acid molecule in which a 5′ portion of the chimeric nucleic acid molecule is from a TMPRSS2 gene and a 3′ portion of the chimeric nucleic acid molecule is from an ERG gene.
Dependencies are inferred from the claim text.